Impact of Fenebrutinib Treatment on MRI Outcomes and Cerebrospinal Fluid Penetrance in Multiple Sclerosis: Results from the Phase II FENopta Study (S31.004)

Amit Bar‐Or; Michal Dufek; Hrvoje Budinčević; Jelena Drulović; Mario Habek; Le H. Hua; Martin S. Weber; Piia Thomas; Julie Napieralski; David Clayton; Denison Kuruvilla; Qi Qi; Yan Xu; Alexandra Goodyear; Jiwon Oh

doi:10.1212/wnl.0000000000205299

April 9, 2024Neurology

Impact of Fenebrutinib Treatment on MRI Outcomes and Cerebrospinal Fluid Penetrance in Multiple Sclerosis: Results from the Phase II FENopta Study (S31.004)

View at Publisher

Ask AI

Bookmark

Share

Abstract

To evaluate the effects of fenebrutinib on MRI outcomes and the ability of fenebrutinib to enter cerebrospinal fluid (CSF) in the ongoing Phase II study FENopta (NCT05119569).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bar‐Or et al. (2024) studied this question.

synapsesocial.com/papers/68e6fcc5b6db643587677385 https://doi.org/10.1212/wnl.0000000000205299

View at Publisher

Ask AI

Bookmark

Share

Impact of Fenebrutinib Treatment on MRI Outcomes and Cerebrospinal Fluid Penetrance in Multiple Sclerosis: Results from the Phase II FENopta Study (S31.004)

Abstract

Discussion

Cite This Study

Impact of Fenebrutinib Treatment on MRI Outcomes and Cerebrospinal Fluid Penetrance in Multiple Sclerosis: Results from the Phase II FENopta Study (S31.004)

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from Neurology

Keep reading

More related papers

More from Neurology